CD4 and diffuse large B-cell lymphoma: This study preliminarily demonstrates the safety of pembrolizumab in relapsed and refractory HIV-related DLBCL patients, indicating that even in patients with relatively low CD4+ T-cell counts (CD4+ T cells < 50 cells/μL), partial remission can be observed.